Search International and National Patent Collections

1. (WO2017037575) A PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE CDK4/6 INHIBITOR RIBOCICLIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER

Pub. No.:    WO/2017/037575    International Application No.:    PCT/IB2016/055043
Publication Date: Fri Mar 10 00:59:59 CET 2017 International Filing Date: Thu Aug 25 01:59:59 CEST 2016
IPC: A61K 31/4439
A61K 31/513
A61K 31/519
A61K 31/52
A61K 31/5517
A61K 31/661
A61P 35/00
Applicants: NOVARTIS AG
CAPONIGRO, Giordano
HORN-SPIROHN, Thomas
LEHAR, Joseph
Inventors: CAPONIGRO, Giordano
HORN-SPIROHN, Thomas
LEHAR, Joseph
Title: A PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE CDK4/6 INHIBITOR RIBOCICLIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER
Abstract:
The present disclosure pertains to a pharmaceutical combination comprising (a) an alpha- isoform specific PI3K inhibitor, (b) a cyclin dependent kinase 4/6 (CDK4/6) inhibitor, and (c) an antimetabolite antineoplastic agent; combined preparations and pharmaceutical compositions thereof; the uses of such a combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.